Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

ClinicalTrials.gov ID: NCT01928537

Public ClinicalTrials.gov record NCT01928537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.

Study identification

NCT ID: NCT01928537
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Traws Pharma, Inc.; Industry
Enrollment: 67 participants

Conditions and interventions

Conditions

Interventions

rigosertib sodium Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2013 (Type not available)
Primary completion: Jun 29, 2017 (Actual)
Completion: Jun 29, 2017 (Actual)
Last update posted: Jun 30, 2020

2013 – 2017

United States locations

U.S. sites: 14
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Stanford University Cancer Center	Stanford	California	94305	—
Rush University Medical Center	Chicago	Illinois	60612	—
University of Chicago Medicine	Chicago	Illinois	60637	—
University of Kansas Cancer Center and Medical Pavilion	Westwood	Kansas	66205	—
Greenbaum Cancer Center University of Maryland	Baltimore	Maryland	21201	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Mayo Clinic	Rochester	Minnesota	55905	—
Mount Sinai Medical Center	New York	New York	10029	—
Columbia University Medical Center	New York	New York	10032	—
New York Presbyterian Hospital-Weill Cornell Medical College	New York	New York	10065	—
Montefiore Medical Center	The Bronx	New York	10461	—
University of Texas Southwestern Medical Center-Parkland Hospital	Dallas	Texas	75235	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01928537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 30, 2020 · Synced Oct 25, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01928537 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →